PTCE · Federal Requirements · 6 min read
FDA Recalls and DSCSA Tracing
- Differentiate among FDA Class I, Class II, and Class III drug recalls and market withdrawals based on their level of health risk.
- Describe the pharmacy technician's role under pharmacist supervision in pulling, quarantining, documenting, and tracing recalled inventory.
- Explain the requirements of the Drug Supply Chain Security Act (DSCSA), including product identifiers, transaction records, and procedures for suspect and illegitimate products.
FDA Drug Recall Classifications and Market Withdrawals
The Food and Drug Administration (FDA) oversees the removal or correction of marketed drugs that violate legal standards or present safety hazards. Drug recalls can be voluntarily initiated by the manufacturer or requested by the FDA. When a recall occurs, the FDA assigns it a specific classification based on the potential health hazard posed by the product. Understanding these classifications helps pharmacy staff quickly assess the urgency of removing a medication from circulation.
A Class I recall is the most urgent and dangerous classification of FDA drug recalls. It involves a situation where there is a reasonable probability that the product will cause serious adverse health consequences or death. For example, a Class I recall might be issued if there is a label mix-up on a high-potency medication, which could lead to severe toxicity or underdosing of a critical therapy, or if an injectable product is found to have contamination with a fatal pathogen.
A Class II recall involves a situation where exposure to the product may cause temporary or medically reversible adverse health consequences, and the probability of serious adverse health consequences is considered remote. An everyday example in pharmacy practice is an under-strength antibiotic; if the reduced potency could cause temporary or medically reversible harm while serious harm remains unlikely, it falls under Class II.
A Class III recall involves products that violate FDA standards but are not likely to cause adverse health consequences. For instance, a minor labeling or container defect that is unlikely to cause adverse health consequences may result in a Class III recall. However, pharmacy staff must be cautious: an unusual odor from a medication container requires careful assessment because an unexpected smell could indicate a more serious problem than a simple minor defect. Finally, a market withdrawal occurs when a product has a minor defect that would not be subject to FDA legal action, such as a minor cosmetic issue.
| Classification | Health Risk Level | Core Criteria and Examples |
|---|---|---|
| Class I | Highest danger; reasonable probability of serious adverse health consequences or death | Most urgent recall class. Examples: label mix-up on a high-potency medication or contamination with a fatal pathogen. |
| Class II | Temporary or medically reversible adverse health consequences; serious harm remote | Intermediate urgency. Example: an under-strength antibiotic when reduced potency causes temporary or reversible harm and serious harm is unlikely. |
| Class III | Violation of FDA standards, but not likely to cause adverse health consequences | Lowest recall urgency. Example: minor labeling or container defect. Note: an unusual odor requires assessment as it could indicate a more serious issue. |
| Market Withdrawal | No formal health consequence; not subject to FDA legal action | Minor or cosmetic defect that does not violate statutory standards to the level of legal action. |
Common mistakes
- Assuming a Class III recall can cause minor or reversible physical harm. Class III recalls violate FDA standards but are not likely to cause adverse health consequences at all; reversible harm falls under Class II.
- Advising a concerned patient to stop taking a recalled medication. While technicians can pull recalled stock and review dispensing history, clinical assessment and counseling on whether to discontinue therapy belong exclusively to the pharmacist.
- Believing that an illegitimate product determination requires only routine documentation. An illegitimate-product determination requires electronic notification to the FDA using Form FDA 3911 and notification, within 24 hours of the determination, to immediate trading partners that may have received the product.
- Discarding or shredding DSCSA transaction data and investigation files after standard two-year prescription record schedules. DSCSA transaction documentation and suspect product investigation records must be kept for at least six years.
Key points
- FDA recalls are divided into three classes: Class I (reasonable probability of serious adverse health consequences or death), Class II (temporary or medically reversible adverse consequences, serious harm remote), and Class III (violates standards but not likely to cause adverse consequences), while market withdrawals address minor issues not subject to FDA legal action.
- Under pharmacist supervision, technicians identify affected inventory using the recall notice (matching NDC, lot number, and expiration date), immediately remove it from active shelves, and place it into a dedicated, labeled quarantine area.
- Technicians assist with documenting recalled stock, preparing returns or destructions, and searching dispensing history, but clinical judgment, patient counseling, and therapy discontinuation advice remain strictly the pharmacist's responsibility.
- The DSCSA establishes package-level tracing for covered human prescription drugs using a 2D data matrix barcode containing an NDC, a unique serial number up to 20 alphanumeric characters, a lot number, and an expiration date.
- For DSCSA-covered products, pharmacies must trade only with authorized trading partners and retain applicable transaction documentation for at least six years.
- A suspect product is potentially counterfeit, diverted, stolen, fraudulent, or adulterated with serious health risk, whereas an illegitimate product has credible evidence confirming these conditions.
- Suspect inventory must be promptly quarantined using physical segregation or another effective procedure permitted by law; within 24 hours after an illegitimate-product determination, the pharmacy must notify the FDA electronically using Form FDA 3911 and notify immediate trading partners that may have received the product.
Practice this section
Explained PTCE Federal Requirements questions, no account needed. PTCE Federal Requirements practice test
The full lesson continues with 3 more sections with exam tips, audio in English and Spanish, 5 Check yourself questions and 20 flashcards.
- 1 month
$44.99$22.49 - 3 months
$131.99$65.99 - Lifetime
$269.99$134.99
One payment, no subscription.
See PTCE plansAlready a member? Log in
Sample lesson: Controlled Substance Prescription Rules25 practice questions on this exam
Each PTCE practice test has 25 original questions with the answers explained. No account needed.
Open the PTCE practice testsOriginal lesson written for PTCE practice · updated October 14, 2026. Exam names are trademarks of their owners; tests.global is not affiliated with them.